Porto-sinusoidal vascular disorder after trastuzumab emtansine (T-DM1) therapy in HER2-positive breast cancer
Clinical Journal of Gastroenterology · 28.10.2026
DOI: 10.1007/s12328-026-02473-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Journal of Gastroenterology, online erschienen am 28.10.2026. Verfasst von Ryuta Shigefuku und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan. shigefuku@med.m…. Die Arbeit nennt 23 Literaturangaben.
Abstract (Originalsprache)
Aim
Trastuzumab emtansine (T-DM1), an antibody–drug conjugate targeting human epidermal growth factor receptor 2 (HER2), is used for HER2-positive breast cancer. Although hepatotoxicity and thrombocytopenia are recognized adverse events of T-DM1, long-term hepatic vascular complications associated with this treatment remain poorly characterized. We report a case of porto-sinusoidal vascular disorder (PSVD) with noncirrhotic portal hypertension (NCPH) associated with prolonged T-DM1 therapy.
Methods
We retrospectively reviewed the clinical course, serial laboratory data, imaging findings, endoscopic findings, and liver histopathology of a woman in her 70s with recurrent HER2-positive breast cancer who received prolonged T-DM1 therapy.
Results
After prior maintenance therapy with trastuzumab and pertuzumab, the patient received 60 cycles of T-DM1. During treatment, progressive thrombocytopenia developed. Serial computed tomography demonstrated splenomegaly, portal vein dilatation, and the development of portosystemic collateral vessels. Upper gastrointestinal endoscopy revealed newly developed esophageal varices. Laboratory evaluation excluded viral, autoimmune, and metabolic liver diseases. Liver biopsy showed focal sinusoidal dilatation and obliterative portal venopathy without cirrhotic architectural distortion, consistent with PSVD. Retrospective imaging review showed that splenomegaly had developed approximately 12 months after the initiation of T-DM1 therapy. Splenomegaly and platelet counts remained unchanged 2 years after T-DM1 discontinuation, whereas spleen stiffness increased.
Conclusions
This case suggests that prolonged exposure to T-DM1 may cause sinusoidal endothelial injury and lead to PSVD with portal hypertension. Progressive thrombocytopenia and splenomegaly during T-DM1 therapy may represent early clinical indicators of this complication. Careful long-term monitoring for signs of portal hypertension should be considered in patients receiving prolonged T-DM1 treatment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan. shigefuku@med.mie-u.ac.jp.
- Department of Medical Oncology, Mie University Graduate School of Medicine, 2-174, Tsu, Mie, 514-8507, Japan.
- Department of Gastroenterology and Hepatology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan.
- Department of Gastroenterology, Murase Hospital, 3-12-10, Suzuka, Mie, 513-0801, Japan.
Zitieren
APA
Shigefuku, R., Saito, K., Iwasa, M., Tsukimoto, M., Tamai, Y., Fujiwara, N., Tameda, M., Ogura, S., Tanaka, H., & Nakagawa, H. (2026). Porto-sinusoidal vascular disorder after trastuzumab emtansine (T-DM1) therapy in HER2-positive breast cancer. Clinical Journal of Gastroenterology. https://doi.org/10.1007/s12328-026-02473-3
Vancouver
Shigefuku R, Saito K, Iwasa M, Tsukimoto M, Tamai Y, Fujiwara N, et al. Porto-sinusoidal vascular disorder after trastuzumab emtansine (T-DM1) therapy in HER2-positive breast cancer. Clinical Journal of Gastroenterology. 2026. doi:10.1007/s12328-026-02473-3
BibTeX
@article{Shigefuku2026,
author = {Shigefuku, Ryuta and Saito, Kanako and Iwasa, Motoh and Tsukimoto, Mone and Tamai, Yasuyuki and Fujiwara, Naoto and Tameda, Masahiko and Ogura, Suguru and Tanaka, Hideaki and Nakagawa, Hayato},
title = {Porto-sinusoidal vascular disorder after trastuzumab emtansine (T-DM1) therapy in HER2-positive breast cancer},
journal = {Clinical Journal of Gastroenterology},
year = {2026},
doi = {10.1007/s12328-026-02473-3}
}
EUVIMED